Chest
EditorialsPulmonary Hypertension: From an Orphan Disease to a Public Health Problem
References (12)
- et al.
Primary pulmonary hypertension
Lancet
(2003) - et al.
Risk factors for pulmonary arterial hypertension
Clin Chest Med
(2001) - et al.
Registry and survival in Chinese patients with idiopathic and familial pulmonary arterial hypertension
Chest
(2007) - et al.
Global alliance against chronic respiratory diseases
Allergy
(2007) - et al.
Clinical classification of pulmonary hypertension
J Am Coll Cardiol
(2004) - et al.
Pulmonary arterial hypertension in France: results from a national registry
Am J Respir Crit Care Med
(2006)
Cited by (41)
Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil
2019, IJC Heart and VasculatureCitation Excerpt :Predictive models have been developed and validated in idiopathic, hereditary, and anorexigen-associated PAH, but their usefulness in estimating the survival of patients with World Health Organization (WHO) group I PAH of all etiologies is unclear [7]. Schistosomiasis may be the most prevalent cause of PAH worldwide due to its global distribution and, until recently, its underestimated morbidity [8–10]. Recognized by WHO as a neglected disease, schistosomiasis is endemic in many developing countries, where poverty and poor basic sanitation result in the population coming in to contact with contaminated water during their daily activities.
Heritable and idiopathic forms of pulmonary arterial hypertension
2019, Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics: Cardiovascular, Respiratory, and Gastrointestinal DisordersHeritable and Idiopathic Forms of Pulmonary Arterial Hypertension
2013, Emery and Rimoin's Principles and Practice of Medical Genetics2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
2023, European Respiratory Journal2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
2022, European Heart Journal
Dr. Humbert is Professor, Centre National de Référence sur l'Hypertension Artérielle Pulmonaire, Hôpital Antoine-Béclère, Université Paris-Sud, Assistance Publique - Hôpitaux de Paris. Dr. Khaltaev is Professor, World Health Organization. Dr. Bousquet is Professor, Clinique des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Université de Montpellier. Dr. Souza is Professor, Pulmonary Hypertension Unit, Pulmonary Department, University of Sao Paulo.
Drs. Humbert and Souza have relationships with drug companies including Actelion, Encysive, GlaxoSmithKline, Schering, Pfizer, and United Therapeutics. In addition to being investigators in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. Drs. Khaltaev and Bousquet have no conflicts of interest to disclose.